Looking At Pfenex Inc

TL;DR

Phoenix is a biotech firm focused on research and development, with a healthy financial position and positive market sentiment.

Transcript

hello I'm at job linen welcome to pink diamond the show that digs deep into the pink sheet markets to find diamonds in the rough now behind the scenes here at investing channel TV we put a lot of effort into researching the best opportunities for you guys so today we're going to take a look at a firm that also puts in a huge focus on research to Ph... Read More

Key Insights

• 💪 Phoenix is a biotech firm with a strong emphasis on research and development.
• ❓ The company's proprietary platform focuses on recombinant protein production.
• 🧡 Phoenix has a range of products, partnerships, and government funding projects in various stages of development.
• ❓ Recent headlines show progress in studies and exclusive commercial partnerships.
• 🪐 Financially, Phoenix has a healthy balance sheet with positive net tangible assets.
• ✋ The stock has performed well in 2019, with potential to retest the annual high.
• 😅 Interest in Phoenix is high, as reflected in the put call ratio and hot searches.

Questions & Answers

Q: What is Phoenix's proprietary platform and what does it focus on?

Phoenix's proprietary platform is the Phoenix expression technology platform, which focuses on recombinant protein production. It synthesizes DNA strands to create gene sequences that aren't found in nature.

Q: What are some of Phoenix's ongoing projects?

Phoenix has ongoing projects, including partnerships with other biotech firms and government-funded projects such as the production of anthrax vaccine. Some projects are in the research phase, while others are awaiting regulatory approval.

Q: What are the recent headlines regarding Phoenix?

In mid-October, Phoenix announced the successful completion of the PF 708 comparative study and submitted it to the FDA. They also announced exclusive commercial partnerships for PF 708 in South Korea, Canada, and Israel.

Q: How are Phoenix's financials looking?

Phoenix experienced a slowdown in sales in the last quarter, but has a healthy balance sheet with positive net tangible assets. While income is negative, the company has cash reserves.

Summary & Key Takeaways

• Phoenix is a biotech firm rooted in research and development, with a market cap of $291 million.

• The company's proprietary platform, the Phoenix expression technology platform, focuses on revolutionary recombinant protein production.

• Phoenix has a range of products, partnerships, and government funding projects at various stages of research and commercial development.